Tamoxifen and toremifene cause impairment of learning and memory function in mice

被引:45
作者
Duo, C [1 ]
Wu, CF [1 ]
Bin, S [1 ]
Yong, MX [1 ]
机构
[1] Shenyang Pharmaceut Univ, Dept Pharmacol, Shenyang 110015, Peoples R China
关键词
tamoxifen; toremifene; learning; memory; acquisition; consolidation; retrieval; step-down; step-through; T-maze;
D O I
10.1016/S0091-3057(01)00656-6
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 [法学]; 0303 [社会学]; 030303 [人类学]; 04 [教育学]; 0402 [心理学];
摘要
Tamoxifen (TAM) and toremifene (TOR) are two antiestrogen agents frequently used in the treatment of breast cancer. They are currently being assessed as the prophylactic for patients at high risk of developing tumors. However, the side effects of these drugs on memory function have drawn attention in clinical usage. In the present study, it is demonstrated in mice that TAM and TOR significantly shortened the escaping latency or increased the number of errors, respectively, by using the step-down and step-through passive avoidance tests. By using an appetitively motivated task in T-maze, it is demonstrated that TAM and TOR significantly delayed the latency of finding food in well-trained mice. TAM appeared to impair memory consolidation and retrieval processes, rather than acquisition of memory, whereas TOR appeared to impair acquisition, consolidation, and retrieval processes. These results provide experimental support for the clinical findings that have shown that these drugs impaired memory function in patients routinely taking the drugs and suggest that caution should be taken for using these drugs as the prophylactics for those at risk of developing tumors. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:269 / 276
页数:8
相关论文
共 35 条
[1]
Inhibition of ligand-gated cation-selective channels by tamoxifen [J].
Allen, MC ;
Newland, C ;
Valverde, MA ;
Hardy, SP .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 354 (2-3) :261-269
[2]
Biegon A, 1996, CANCER RES, V56, P4328
[3]
POSTMENOPAUSAL ESTROGEN REPLACEMENT THERAPY AND THE RISK OF ALZHEIMERS-DISEASE - A POPULATION-BASED CASE-CONTROL STUDY [J].
BRENNER, DE ;
KUKULL, WA ;
STERGACHIS, A ;
VANBELLE, G ;
BOWEN, JD ;
MCCORMICK, WC ;
TERI, T ;
LARSON, EB .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1994, 140 (03) :262-267
[4]
Cognitive function in breast cancer patients receiving adjuvant chemotherapy [J].
Brezden, CB ;
Phillips, KA ;
Abdolell, M ;
Bunston, T ;
Tannock, IF .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (14) :2695-2701
[5]
Carr D. B., 1997, American Journal of Medicine, V103, p3S, DOI 10.1016/S0002-9343(97)00262-3
[6]
Uterotrophic effects of tamoxifen, toremifene, and raloxifene do not predict endometrial cell proliferation in the ovariectomized CD1 mouse [J].
Carthew, P ;
Edwards, RE ;
Nolan, BM .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1999, 158 (01) :24-32
[7]
MEMORY ENHANCING EFFECTS OF GRANISETRON (BRL-43694) IN A PASSIVE-AVOIDANCE TASK [J].
CHUGH, Y ;
SAHA, N ;
SANKARANARAYANAN, A ;
SHARMA, PL .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, 203 (01) :121-123
[8]
Clarke M, 1998, LANCET, V351, P1451
[9]
High frequency of adenomyosis in postmenopausal breast cancer patients treated with tamoxifen [J].
Cohen, I ;
Beyth, Y ;
Shapira, J ;
Tepper, R ;
Fishman, A ;
Cordoba, M ;
Bernheim, J ;
Yigael, D ;
Altaras, MM .
GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 1997, 44 (03) :200-205
[10]
Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study [J].
Fisher, B ;
Costantino, JP ;
Wickerham, DL ;
Redmond, CK ;
Kavanah, M ;
Cronin, WM ;
Vogel, V ;
Robidoux, A ;
Dimitrov, N ;
Atkins, J ;
Daly, M ;
Wieand, S ;
Tan-Chiu, E ;
Ford, L ;
Wolmark, N .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) :1371-1388